Primaquine for uncomplicated Plasmodium vivax malaria in children younger than 15 years: a systematic review and individual patient data meta-analysis
Robert J Commons,Megha Rajasekhar,Elizabeth N Allen,Daniel Yilma,Palang Chotsiri,Tesfay Abreha,Ishag Adam,Ghulam Rahim Awab,Bridget E Barber,Larissa W Brasil,Cindy S Chu,Liwang Cui,Peta Edler,Margarete do Socorro M Gomes,Lilia Gonzalez-Ceron,Matthew J Grigg,Muzamil Mahdi Abdel Hamid,Jimee Hwang,Harin Karunajeewa,Marcus V G Lacerda,Simone Ladeia-Andrade,Toby Leslie,Rhea J Longley,Wuelton Marcelo Monteiro,Ayodhia Pitaloka Pasaribu,Jeanne Rini Poespoprodjo,Caitlin L Richmond,Komal Raj Rijal,Walter R J Taylor,Pham Vinh Thanh,Kamala Thriemer,José Luiz F Vieira,Nicholas J White,Lina M Zuluaga-Idarraga,Lesley J Workman,Joel Tarning,Kasia Stepniewska,Philippe J Guerin,Julie A Simpson,Karen I Barnes,Ric N Price,WorldWide Antimalarial Resistance Network Paediatric Primaquine Vivax Study Group,Bipin Adhikari,Mohammad Shafiul Alam,Nicholas M Anstey,Ashenafi Assefa,J Kevin Baird,Sarah C Boyd,Nguyen H Chau,Nicholas Pj Day,Tamiru Shibiru Degaga,Arjen M Dondorp,Annette Erhart,Marcelo U Ferreira,Prakash Ghimire,Wasif A Khan,Benedikt Ley,Asrat H Mekuria,Ivo Mueller,Mohammad N Naadim,Francois Nosten,David J Price,Sasithon Pukrittayakamee,Mark Rowland,Jetsumon Sattabongkot,Guilherme SuarezKurtz,Inge Sutanto,Lorenz von Seidlein,Timothy William,Charles J Woodrow,Adugna Woyessa
DOI: https://doi.org/10.1016/S2352-4642(24)00210-4
Abstract:Background: Primaquine, the only widely available treatment to prevent relapsing Plasmodium vivax malaria, is produced as 15 mg tablets, and new paediatric formulations are being developed. To inform the optimal primaquine dosing regimen for children, we aimed to determine the efficacy and safety of different primaquine dose strategies in children younger than 15 years. Methods: We undertook a systematic review (Jan 1, 2000-July 26, 2024) for P vivax efficacy studies with at least one treatment group that was administered primaquine over multiple days, that enrolled children younger than 15 years, that followed up patients for at least 28 days, and that had data available for inclusion by June 30, 2022. Patients were excluded if they were aged 15 years or older, presented with severe malaria, received adjunctive antimalarials within 14 days of diagnosis, commenced primaquine more than 7 days after starting schizontocidal treatment, had a protocol violation in the original study, or were missing data on age, sex, or primaquine dose. Available individual patient data were collated and standardised. To evaluate efficacy, the risk of recurrent P vivax parasitaemia between days 7 and 180 was assessed by time-to-event analysis for different total mg/kg primaquine doses (low total dose of ∼3·5 mg/kg and high total dose of ∼7 mg/kg). To evaluate tolerability and safety, the following were assessed by daily mg/kg primaquine dose (low daily dose of ∼0·25 mg/kg, intermediate daily dose of ∼0·5 mg/kg, and high daily dose of ∼1 mg/kg): gastrointestinal symptoms (vomiting, anorexia, or diarrhoea) on days 5-7, haemoglobin decrease of at least 25% to less than 7g/dL (severe haemolysis), absolute change in haemoglobin from day 0 to days 2-3 or days 5-7, and any serious adverse events within 28 days. This study is registered with PROSPERO, CRD42021278085. Findings: In total, 3514 children from 27 studies and 15 countries were included. The cumulative incidence of recurrence by day 180 was 51·4% (95% CI 47·0-55·9) following treatment without primaquine, 16·0% (12·4-20·3) following a low total dose of primaquine, and 10·2% (8·4-12·3) following a high total dose of primaquine. The hazard of recurrent P vivax parasitaemia in children younger than 15 years was reduced following primaquine at low total doses (adjusted hazard ratio [HR] 0·17, 95% CI 0·11-0·25) and high total doses (0·09, 0·07-0·12), compared with no primaquine. In 525 children younger than 5 years, the relative rates of recurrence were also reduced, with an adjusted HR of 0·33 (95% CI 0·18-0·59) for a low total dose and 0·13 (0·08-0·21) for a high total dose of primaquine compared with no primaquine. The rate of recurrence following a high total dose was reduced compared with a low dose in children younger than 15 years (adjusted HR 0·54, 95% CI 0·35-0·85) and children younger than 5 years (0·41, 0·21-0·78). Compared with no primaquine, children treated with any dose of primaquine had a greater risk of gastrointestinal symptoms on days 5-7 after adjustment for confounders, with adjusted risks of 3·9% (95% CI 0-8·6) in children not treated with primaquine, 9·2% (0-18·7) with a low daily dose of primaquine, 6·8% (1·7-12·0) with an intermediate daily dose of primaquine, and 9·6% (4·8-14·3) with a high daily dose of primaquine. In children with 30% or higher glucose-6-phosphate dehydrogenase (G6PD) activity, there were few episodes of severe haemolysis following no primaquine (0·4%, 95% CI 0·1-1·5), a low daily dose (0·0%, 0·0-1·6), an intermediate daily dose (0·5%, 0·1-1·4), or a high daily dose (0·7%, 0·2-1·9). Of 15 possibly drug-related serious adverse events in children, two occurred following a low, four following an intermediate, and nine following a high daily dose of primaquine. Interpretation: A high total dose of primaquine was highly efficacious in reducing recurrent P vivax parasitaemia in children compared with a low dose, particularly in children younger than 5 years. In children treated with high and intermediate daily primaquine doses compared with low daily doses, there was no increase in gastrointestinal symptoms or haemolysis (in children with 30% or higher G6PD activity), but there were more serious adverse events. Funding: Medicines for Malaria Venture, Bill & Melinda Gates Foundation, and Australian National Health and Medical Research Council.